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Abstract 
 
A number of clinical trials have examined the effect of L-arginine on lipid profile in recent years; 
however, the results remain equivocal. Therefore, the present study aims to summarize and 
quantitatively examine the available evidence on the effectiveness L-arginine supplementation on 
lipid parameters by employing a systematic review and meta-analytic approach. Online databases 
including PubMed, Scopus, ISI Web of Science, Cochrane library, and Google Scholar were 
searched up to April 2019 for randomized controlled trials that examined the effect of L-arginine 
supplementation on lipid profile in adults. Treatment effects were expressed as weighted mean 
difference (WMD) and the corresponding standard error (SE) in concentrations of serum lipids. To 
estimate the overall effect of L-arginine supplementation, we employed the random-effects model. 
In total, 12 studies were included in the systematic review. The meta-analysis revealed that L-
arginine supplementation did not significantly change the concentrations of total cholesterol 
(WMD: -5.03 mg/dl; 95% CI: - 10.78 to 0.73, P= 0.08, I
2
=39.0%), low-density lipoprotein (WMD: 
-0.47 mg/dl; 95% CI: -3.61 
 
to 2.66, P=0.76, I
2
=0.0%), or high-density lipoprotein (WMD: 0.57 mg/dl; 95% CI: -1.28 to 
 
 
2.43, P=0.54, I
2
=68.4%). A significant reduction was observed only in serum triglyceride (TG) 
levels (WMD: -7.04 mg/dl; 95% CI: -11.42 to -2.67, P˂0.001, I2=0.0%). This meta-analysis 
concludes that L-arginine supplementation can significantly reduce blood TG levels, however, 
there is insufficient evidence to support its hypocholesterolaemic effects. To draw 
straightforward conclusions regarding generalized recommendations for L-arginine 
supplementation for improving lipid profile, there is a need for more well-controlled trials 
targeting exclusively patients with dyslipidaemia. 
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Introduction 
 
 
Cardiovascular diseases (CVDs) are the leading causes of death among non-communicable 
diseases, posing a significant health and economic burden worldwide 
(1; 2)
. The American 
Heart Association reported that 17.7 million people (representing 31% of all global deaths) 
died from CVDs in 2015, and this number is projected to rise to 23.6 million deaths by 2030 
(3)
. Dyslipidemia has been identified as a major risk factor for CVDs 
(4; 5; 6)
. Thus, regulating 
and maintaining an optimal lipid profile is critical for the prevention of CVDs. In this regard, 
statin therapy and diet modification are two of the most commonly prescribed approaches 
(7; 
8)
. However, statins, among other commonly used lipid lowering pharmacotherapies 
(9)
, have 
been established to pose some serious adverse effects, such as myopathies and hepatotoxicity 
(10; 11)
. Thus, there is a demand to identify viable, anti-lipid agents that are able to pose cardio-
protective effects without inducing any side-effects. 
 
L-arginine is a semi-essential amino acid which our body derives either from dietary sources or 
from endogenous metabolism 
(12; 13)
. L-arginine is involved in several biochemical processes, 
including polyamine synthesis, ammonia detoxification, immune modulation, and secretion of 
hormones such as glucagon and growth hormone and insulin 
(14; 15; 16)
. What is more, this amino 
acid produces nitric oxide (NO), a key molecule involved in the regulation of cell metabolism, 
insulin signaling and secretion, neurotransmission and immune system function 
(17; 18)
. It is 
suggested that L-arginine can be useful in improving lipid profile, due to its’ potential to increase 
NO production. Therefore, L-arginine has been investigated as a potentially cardio-protective 
compound, and seven meta-analyses concluded that it can be an effective tool in blood pressure 
management 
(19)
. Several trials investigated the potential of L-arginine supplementation for the 
treatment of abnormal lipid profile, however, the results are inconsistent. For instance, some trials 
report that L-arginine supplementation induced a reduction in circulating concentrations of lipid 
parameters 
(20; 21; 22; 23)
, while others report no 
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significant effect 
(18; 24; 25; 26; 27; 28; 29; 30)
. Discrepancies in the findings may conceivably 
be attributed to the differences in study designs, characteristics of study participants, duration 
and the supplementation dosage applied in the trials. Therefore, we conducted a meta-analysis 
of those randomized controlled trials (RCTs) to examine the efficacy of L-arginine 
supplementation as a lipid-lowering agent. 
 
Methods 
 
 
We conducted and reported the present systematic review and meta-analysis following the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 
(Supplementary Table 1) 
(31)
 for identification, screening, eligibility, and inclusion of articles. 
This study was not prospectively registered. Participants, interventions, comparisons, 
outcomes, and study design (PICOS) are shown in Table 1. 
 
Search strategy 
 
 
To carry out this meta-analysis, two independent investigators (A.H. and E.Gh) performed a 
systematic search of all articles published until April 2019 in the following online databases: 
PubMed, Scopus, Cochrane Library, ISI Web of Science, and Google Scholar. We used the 
following Medical Subject Headings (MeSH) and corresponding keywords: (“arginine” OR 
“L-arginine”) AND (“lipid” OR “hyperlipidaemia” OR “dyslipidemia” OR “cholesterol” OR 
“CHOL” OR “hypercholesterolemia” OR “lipoprotein” OR “hyperlipoproteinemia” OR “high 
density lipoprotein” OR “HDL” OR “low density lipoprotein” OR “LDL” OR “triglyceride” 
OR “TG”) AND ("Intervention Studies" OR "intervention" OR "controlled trial" OR 
"randomized" OR "randomised" OR "random" OR "randomly" OR "placebo" OR 
"assignment"). The two reviewers also performed screening of the reference lists of relevant 
review articles and original papers that were selected for full-text review to identify potential 
eligible studies. Additionally, an email alert service was employed to avoid missing any 
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relevant articles. The language of the retrieved papers was restricted to English, while there 
were no restrictions regarding the year of publication. 
 
Study selection 
 
 
All studies retrieved from the electronic databases and reference lists were entered into endnote 
software (EndNote X6, Thomson Corporation, Stamford, USA) and duplicate studies were 
removed. In the next step, the titles and abstracts of the papers were examined by two 
independent reviewers (A.A and E.Gh) to exclude irrelevant articles. Afterwards, the full texts 
of the remaining publications were read and assessed according to the following four items: 
study design, participants, interventions and outcome measures. Finally, the studies were 
retained if they met the following inclusion criteria: (1) a randomized controlled design; (2) 
reporting the effect of L-arginine on at least one of the lipid profile parameters including total 
cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c), and high-
density lipoprotein cholesterol (HDL-c); (3) intervention duration longer than 4 weeks. Studies 
were excluded if they: (1) involved L-arginine supplementation in combination with some 
drugs or other types of supplements (minerals, vitamins or herbal supplements, unless a 
separate arm controlled the effect of the mixed substance); (2) reported duplicate data (in this 
case, the data with complete follow-up and outcome measures was included), (3) included 
adolescents as the population; (4) were not peer-reviewed articles (protocol or conference 
proceeding). Any disagreements regarding the process of study selection were resolved in 
consultation with the principal investigator (A.H). 
 
Data extraction 
 
 
The major demographic and clinical data from each of the selected studies were screened and 
extracted independently by two investigators (A.H and E.Gh) using a pre-designed Excel sheet. 
Any controversy was solved via discussion with a third, independent researcher to reach a 
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consensus. The extracted information was as follows: the first author’s last name, publication 
year, study design, country, sample size, participants mean age, gender, baseline body mass 
index (BMI), follow-up duration, intervention duration (in weeks), type of intervention, dose 
of L-arginine (g/day), type of control, health status of the participants, and main results. 
Corresponding authors were contacted if there were any missing data. 
 
Quality assessment 
 
 
The Cochrane Collaboration tool 
(32)
 was used for quality assessment, and it includes seven 
items, namely: randomization sequence generation, allocation concealment, blinding of 
participants and personnel, blinding of outcome assessors, incomplete outcome data, selective 
reporting, and other biases. Each domain was classified into three categories: low risk of bias, 
high risk of bias and unclear risk of bias. Finally, the overall quality of the studies was 
categorized into weak, fair, or good, if ˂3, 3, or ≥4 domains were rated as low risk, 
respectively. Quality assessment was performed independently by two reviewers (A.A and 
E.Gh), while any disagreements were resolved by consulting the third reviewer (A.H). 
 
Statistical analysis 
 
 
For carrying out the meta-analysis, we employed the STATA software (version 11; StataCorp). If 
outcome measures were reported in mmol/l, they were converted to mg/dL. The reviewers then 
extracted the mean difference between the baseline and endpoint data and the corresponding 
standard deviations (SD) in both intervention and control groups. If such data were not available, 
the mean difference was obtained by subtracting the mean value of the baseline-point from that of 
the endpoint. If SD of the mean difference was not reported, it was calculated using the following 
formula: SD = square root [(SD pre-treatment) 
2
 + (SD post-treatment) 
2
 – (2 × R × SD pretreatment 
× SD post-treatment)]. To ensure the meta-analysis was not sensitive to the selected correlation 
coefficient (R = 0.5), all analyses were repeated 
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using correlation coefficients of 0.2 and 0.8. Where a standard error (SE) was only reported, 
SD was estimated using the following formula: SD = SE × √n (n being the number of subjects 
in each group). Using random-effects model developed by DerSimonian and Laird
(33)
, the 
summary estimate was pooled as weighted mean difference (WMD) and 95% confidence 
interval (CI). The inconsistency index (I
2
) was used to quantify statistical heterogeneity in the 
meta-analyses, and values greater than 50% were considered indicative of high heterogeneity. 
To identify the source of heterogeneity, subgroup analysis was conducted focusing on: mean 
age, baseline BMI, dose of L-arginine supplementation, study duration, and participant's health 
status. Sensitivity analysis was also performed to explore the extent to which inferences might 
depend on a particular study using the leave-one-out method (i.e. deleting one trail at a time 
and re-calculating the effect size). To assess publication bias, Begg 
(34)
 and Egger's 
(35)
 
regression tests were performed. In all statistical analyses, level of significance was set at P < 
0.05. 
  
Results 
 
 
Flow of study selection 
 
 
A total of 2216 publications were identified after the search of the electronic databases, out of which 755 were removed 
as being duplicate (Figure 1). By reviewing the title and abstracts of the remaining articles, 1438 publications not 
meeting the inclusion criteria were excluded. Subsequently, 23 full-text articles were carefully reviewed and 11 clinical 
trials were excluded because of the following reasons: five studies had a duration of supplementation period less than 4 
weeks, one study enrolled adolescents, two studies involved interventions that were a combination of other components 
together with L-arginine and the design did not enable evaluating L-arginine effect only, one study enrolled less than 
10 participants, and two articles reported the results from a same population. Finally, 12 trials 
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including 15 treatment arms were considered eligible for the systematic review. However, one of 
the included articles 
(28)
 did not report the data required for the meta-analysis. We contacted the 
corresponding author of the study twice, but did not receive any response, and therefore it 
 
was subsequently, excluded, leaving 11 studies for inclusion in the meta-analysis. 
 
 
Study and participant characteristics 
 
 
Characteristics of the included trials are outlined in Table 2. In total, 631 participants were enrolled in 
the selected articles, out of which 359 individuals were allocated to L-arginine supplementation group 
and 272 subjects to the control group. These studies were published between 1996 and 2019 and were 
carried out in the Iran 
(20; 21; 22; 23; 29)
, Italy 
(27)
, Poland 
(18; 24;
 
26)
, Israel 
(28)
, United Kingdom 
(30)
, 
and Germany 
(25)
. All studies except two 
(28; 30)
 adopted a parallel study design. The mean age of the 
participants ranged from 20.86 to 64.5 years old and the mean baseline BMI varied from 23.67 to 38.35 
kg/m
2
. Only one 
(21)
 of included studies 
 
involved exclusively male population, two involved women, and the other trials involved 
 
populations of mixed genders. The follow-up period ranged from 4 to 77 weeks. Daily 
supplementation dosage of L-arginine varied between 1 and 21 g/day in these studies. The health 
status of the included participants was mixed, and included: type 2 diabetes patients 
(22)
, 
postmenopausal women 
(28)
, patients with CVD 
(26)
, subjects with hypercholesterolemia 
(30)
, 
obese individuals 
(18; 20; 24; 29)
, subjects with hypertriglyceridemia 
(25)
, individuals with metabolic 
syndrome 
(23)
, healthy subjects 
(21)
, and those with impaired glucose tolerance and 
 
metabolic syndrome 
(27)
. No major adverse effects attributable to intervention or control
were reported in RCTs. 
 
In a study by Pourghassem Gargari et al. 
(29)
, there were three intervention groups (arginine + 
hypocaloric diet enriched in legumes (HDEL), arginine + HDEL + selenium, HDEL + 
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selenium) and one control group (HDEL). We considered the result of the arginine + HDEL, 
and HDEL groups as one arm and the result of the arginine + HDEL + selenium and HDEL+ 
selenium groups as another arm. Furthermore, Rahimi et al.
(22)
 and Dashtabi et al.
(20)
, 
included 2 different arginine doses in their trials (3 or 6 g/day); therefore, we considered these 
imputations as 4 different arms. 
 
Quality assessment 
 
 
Among 12 studies included in the present review, nine trials 
(18; 20; 21; 23; 24; 25; 26; 27; 29)
 
were categorized as good quality, and 3 trials 
(22; 28; 30)
 were fair quality. The details of the 
risk of bias in individual studies according to the domains used by the Cochrane Collaborations 
tool are provided in Table 3. 
 
Findings from the systematic review 
 
 
The present systematic review revealed that 3 trials 
(20; 21; 22)
 reported that L-arginine 
supplementation managed to reduce TC levels, while 8 studies 
(18; 23; 25; 26; 27; 28; 29; 30)
 
failed to find any significant effect on this parameter. In terms of changes in TG levels, 3 trials 
observed a significant reduction after L-arginine supplementation in (20; 21; 23), while 8 studies 
(18; 22; 25; 26;
 
27; 28; 29; 30)
 did not find such an effect. Evidence points out that arginine may 
pose favorable effects on LDL-c concentration as well - three trials 
(20; 21; 22)
 found that 
supplementation induced a decrease in plasma LDL-c, while other trials report no significant 
changes on this outcome 
(23; 24; 25; 26; 27; 28; 29; 30)
. Finally, L-arginine may induce favorable 
changes in HDL-c levels as confirmed in 2 trials
(20; 21)
, however, the remaining studies
(22; 23; 
24; 25; 26; 27; 28; 29; 30)
 did not reach the same conclusion. 
 
Findings from the meta-analysis 
 
 
In total, we pooled the data from 13 arms corresponding to 10 studies 
(18; 20; 21; 22; 23; 25; 26; 27; 29;
 
 
30) which included 561 participants, to estimate the effect of L-arginine supplementation on  
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plasma TC levels. After employing a meta-analysis random-effects model, we found that L-
arginine supplementation did not significantly affect serum TC levels (WMD: -5.03 mg/dl; 
95% CI: -10.78 to 0.73, P= 0.08) (Figure2). The between-study heterogeneity was non-
significant (P=0.07, I
2
=39.0%). Subgroup analysis based on participants' mean age, baseline 
BMI, study duration, participants health status, and L-arginine dose confirmed that the effect 
is not statistically significant in none of the subgroups (Table 4). Findings from the sensitivity 
analysis revealed that the exclusion of any single study from the analysis did not alter the 
overall effect. 
 
Thirteen arms from 10 studies 
(18; 20; 21; 22; 23; 25; 26; 27; 29; 30)
 including 561 participants reported 
the effect of L-arginine on serum TG concentration. The pooled effect demonstrated a significant 
decrease in TG levels following L-arginine supplementation (WMD: -7.04 mg/dl; 95% CI: -11.42 
to -2.67, P˂0.001) with a non-significant heterogeneity among included studies (P=0.59, I
2
=0.0%) 
(Figure 3). Subgroup analysis based on participants' mean age, baseline BMI, study duration, 
participants health status, and L-arginine dose revealed that the effect was significant in studies 
which included participants with a mean age≥50 years (WMD: - 9.08mg/dl; 95% CI: -16.70 to -
1.45, P=0.02), a baseline BMI≥30 kg/m
2
(WMD: -9.86mg/dl; 95% CI: -16.22 to -3.50, P˂0.001), 
L-arginine dose˂6 g/day (WMD: -7.89mg/dl; 95% CI: - 15.04 to -0.73, P=0.03), type two
diabetes/metabolic syndrome (WMD: -11.77mg/dl; 95% CI: 
 
-19.39 to -4.14, P˂0.001), and intervention duration ≥10 weeks (WMD: -9.21mg/dl; 95% CI: 
-15.20 to -3.21, P˂0.001) (Table 4). The sensitivity analysis demonstrated that by removing 
the study conducted by Bahrami et al.
(23)
, the effect of L-arginine supplementation on TG 
levels becomes non-significant (WMD: -4.65 mg/dl; 95% CI: -9.51 to 0.19, P=0.06). 
 
The impact of L-arginine supplementation on LDL-c levels was assessed in 10 trials 
 
with 13 treatment arms including 533 participants. The meta-analysis 
 
revealed that L-arginine supplementation did not significantly affect LDL-c levels (WMD: - 
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0.47 mg/dl; 95% CI: -3.61 to 2.66, P=0.76) while the heterogeneity among the included studies 
was not significant (P=0.53, I
2
=0.0%) (Figure 4). The subgroup analysis based on participants' 
mean age, baseline BMI, study duration, participants health status, and L-arginine dose also 
showed that the effect is not statistically significant in none of the subgroups (Table 4). 
Furthermore, removing each individual study by sensitivity analysis did not change the pooled 
effect size. 
 
Ten studies including 533 participants from 13 intervention arms 
 
measured changes in serum HDL-c concentrations following L-arginine supplementation. Pooled 
results from the random-effects model revealed that L-arginine supplementation had no significant 
effect on serum HDL-c levels (WMD: 0.57 mg/dl; 95% CI: -1.28 to 2.43, P=0.54) (Figure 5). 
There was a significant heterogeneity among the studies (P˂0.001, I
2
=68.4%), and the subgroup 
analysis showed that baseline BMI (˂30 kg/m
2
: P=0.96, I
2
=0.0%), duration of follow up (˂10 
weeks: P=0.23, I
2
=25.6%), participants health status (dyslipidemia: P=0.69, 
 
I
2
=0.0%), or type two diabetes/metabolic syndrome: P=0.93, I
2
=0.0%), and L-arginine dosage 
 
 
(˂6 g/day: P=0.96, I2=0.0%) were significant contributors to the between-study heterogeneity. 
Besides, the subgroup analysis showed that L-arginine supplementation increases HDL levels 
in trials with a follow-up duration ˂10 weeks (WMD: 2.04 mg/dl; 95% CI: 0.52 to 3.56, 
P=0.01) (Table 4). Findings from the sensitivity analysis revealed that the exclusion of any 
single study from the analysis did not alter the overall effect. 
 
Publication bias 
 
 
Although the visual inspection of funnel plots showed slight asymmetries, no significant 
publication bias was detected in the meta-analyses in the case of TC (Begg's test, P=0.54; 
Egger's test, P=0.45), TG (Begg's test, P=0.54; Egger's test, P=0.56), LDL-c (Begg's test, 
P=0.39; Egger's test, P=0.80), or HDL-c (Begg's test, P=0.39; Egger's test, P=0.86). 
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Discussion 
 
 
To the best of our knowledge, this study is the first systematic review and meta-analysis that 
measured the effect of L-arginine supplementation on lipid profile by summarizing the data 
from published RCTs. Our results indicate that L-arginine supplementation was not able to 
induce changes in TC, LDL-c, and HDL-c concentrations however it did induce a significant 
decrease in TG levels. Subgroup analyses further confirmed that L-arginine supplementation 
imposed a significant TG-lowering effect in studies that implemented long-term treatment (≥10 
weeks), as well as in studies where participants had a baseline BMI≥30 kg/m2, mean age ≥50 
years, supplementation dosage ˂6 g/day, and where participants were type 2 diabetes or 
metabolic syndrome patients. Although the pooled effect size of L-arginine supplementation 
on HDL-c levels was not significant, subgroup analysis revealed that this effect was significant 
only in studies that lasted longer than 10 weeks. 
 
In this meta-analysis, we concluded that L-arginine was able to induce favorable changes only 
on TG levels, while this was not observed in the case of other lipid parameters. The possible 
explanation for the observed lack of significant effect for all parameters except TG might be 
the fact that the included population had only TG levels above the recommended upper value 
according to the definition of metabolic syndrome. Thus, this observation may imply that 
individuals with higher TG levels are better respondents to L-arginine therapy. 
 
The biological plausibility of lipid-associated L-arginine implications comes from the existing 
relationship between this amino acid and glucose metabolism. Human clinical trials have concluded 
so far that L-arginine can be an effective tool in reducing blood glucose levels in diabetes type 2 
patients 
(36)
, in increasing insulin sensitivity 
(37)
 and in improving insulin resistance 
(38)
. One of 
the proposed explanations for the observed results is that insulin resistance of the adipocytes can 
lead to an increased release of fatty acids into the circulation. 
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Increased free fatty acid flux reaches the liver where it stimulates the assembly and secretion 
of very-low-density lipoprotein, which results in hypertriglyceridemia 
(39; 40)
. Another 
possible mechanism might be related to the lowering effect of L-arginine on blood glucose, the 
decrease in blood glucose levels leads to an increase in the concentration of cyclic adenosine 
monophosphate which in turn decreases TG levels 
(41; 42)
. Therefore, given the beneficial role 
of L-arginine in the glucose homeostasis, it is proposed that supplementation with this amino 
acid can lower serum TG levels 
(42; 43)
. 
 
Other putative mechanisms may be related to the arginine nitric oxide synthase pathway. All 
nitric oxide synthase isoforms utilize L-arginine as a substrate, which undergoes a two-step 
metabolic conversion, yielding at the end L-citrulline and NO 
(44)
. Elevated NO production, 
consequently increases lipoprotein lipase activity
(45)
 and finally, by performing hydrolysis of 
TGs it reduces its concentration in the plasma 
(25; 46)
. Animal study data also confirm L-
arginine to be an effective lipid lowering agent by decreasing the white fat expansion, and 
improving serum TG levels in rats
(41; 47)
. 
 
A neutral effect of L-arginine supplementation on TC, LDL-c and HDL-c was observed in the present
meta-analysis. Subgroup analysis of the effect of L-arginine supplementation on cholesterol or
lipoprotein levels did not moderate the outcome. These findings are generally in 
 
line with the majority of individual studies selected for this review. Only three studies
(20; 21; 22) showed a
significant change in TC, LDL-c and HDL-c levels and others failed to find such a 
  
relationship. Furthermore, not all animal studies reported consistent results; as, reducing
(48; 49) or
even increasing effect of L-arginine supplementation on cholesterol level has been 
reported
(50)
. Madeira et al. reported that dietary L-arginine supplementation increase 
concentrations of total lipids, very low-density lipoproteins (VLDL) and TG
(51)
. However, Hu 
 
et al.
(52)
reported that L-arginine supplementation decrease TG, and cholesterol levels in the  
 
plasma. In addition, He et al.
(53)
 showed that L-arginine supplementation reduces VLDL, lipids 
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and TG concentrations in piglets. However, Some animal studies reported that L-arginine might 
reduce cholesterol or lipoprotein levels by these mechanisms: 1) decrease the expression of hepatic 3-
hydroxyl-3-methylglutaryl-CoA reductase mRNA, which shows interaction of L- 
 
arginine with cholesterol metabolism
(54)
2) increased the lipolysis as well as the oxidation of fatty
acids; 3) increase plasma adiponectin levels which improved FFAs β-oxidation. On the other hand,
others reported that possible TC increasing effect of L-arginine could be due to 
 
increased fat accretion in the carcass
(55)
. L-arginine can also increase the level of HDL-c 
 
 
through its effect on inflammation
(47; 56; 57)
. 
 
 
 
L-arginine has generally been well tolerated when administered in small doses (≤ 30 g/day) 
(58)
. There were some reported benign side effects, however, which include: abdominal pain, 
bloating, nausea and vomiting, airway inflammation, diarrhea, hypotension, worsening of 
asthma, and allergic reactions 
(58; 59; 60)
. Furthermore, given that a major part of L-arginine is 
metabolized to ornithine and urea
(58; 61)
, patients with gout or renal function impairment should 
pay special caution when consuming it. Finally, due to its vasodilating properties, L-arginine 
has also been shown to interfere with certain medications (including Viagra and blood pressure 
medications) thus imposing negative reactions.
(58)
. 
 
This meta-analysis has certain limitations that should be noted. Firstly, the included studies 
involved individuals with different health status, resulting in a heterogeneous sample. 
Secondly, the sample sizes of individual trials were small, thus our results might more easily 
suffer from sample imbalances and an influence of baseline confounding factors. Third, the 
influence of gender remains unknown, since there was just one article that involved men. 
Women have different sex hormones compared with men that may affect lipid profile, thus 
implying that L-arginine may impose gender-dependent effects. Lastly, most RCTs were not 
primarily designed to assess the effects of L-arginine on lipid concentrations. In order to draw 
straightforward conclusions regarding recommending L-arginine supplementation as a lipid 
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lowering agent, we need more RCTs designed to specifically address this issue in a target 
population of patients with abnormal lipid profile. 
 
This study also has its strengths. It is only systematic review and meta-analysis to investigate the 
effect of arginine supplementation on lipid profile. Our systematic search makes it unlikely that
large reports were missed, and error and bias were minimized by independent, duplicate 
decisions on whole process of review by adhering to the PRISMA guidelines. Also, subgroup 
analysis and assessment of mean age, baseline BMI, dose of L-arginine, study duration, and 
health status were done on the overall effect sizes. 
 
 
Conclusion 
 
 
The current systematic review and meta-analysis demonstrated that L-arginine 
supplementation leads to a significant reduction in TG levels. However, no significant effect 
was observed in the case of other lipid parameters including TC, LDL-c, and HDL-c. In order 
to confirm the results of our study, further clinical trials that exclusively examine the effects of 
L-arginine on participants with dyslipidemia are required. 
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Legends of figures: 
 
 
Figure 1. PRISMA flow diagram of study selection process 
 
 
Figure 2. Forest plot of the effect of L-arginine supplementation on TC 
 
 
Figure 3. Forest plot of the effect ofL-arginine supplementation on TG 
 
 
Figure 4. Forest plot of the effect of L-arginine supplementation on LDL-c 
 
 
Figure 5. Forest plot of the effect of L-arginine supplementation on HDL-c 
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Table 1: PICOS criteria used to perform the systematic review and Meta-analysis 
 
Parameter Criteria 
  
Population Adults 
  
Intervention Arginine 
  
Comparator Matched control group 
  
Outcome Circulating TC, TG, LDL-c, and HDL-c 
  
Setting or study design Randomized controlled trials 
  
 
TC, total cholesterol; TG, triglyceride; LDL-c, low density lipoprotein cholesterol; HDL-c, 
low-density lipoprotein cholesterol 
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First author Country Sample size RCT design Gender Mean age Mean BMI Duration Target Intervention Control Results 
(publication year)   (blinding)  (year) (kg/m2) (week) population (name and daily dose)   
            
Clarkson UK 27 Crossover Both 29 26 4 Subjects with 21 g/day arginine Placebo TC ↔ 
(1996)   (Yes)     hypercholesterolemia   TG ↔ 
           LDL-c ↔ 
           HDL-c↔ 
Blum Israel 10 Crossover Women 55 26.6 4 Postmenopausal 9 g/day arginine Placebo TC ↔ 
(2000)   (Yes)     women   TG ↔ 
           LDL-c ↔ 
           HDL-c↔ 
Lucotti Poland 30 Parallel Both 64.5 34 26 Patients with CVD 6.4 g/day arginine Placebo TC ↔ 
(2009)   (Yes)        TG ↔ 
           LDL-c↔ 
           HDL-c↔ 
Schulze Germany 33 Parallel Both 54.3 28.40 6 Subjects with 3 g/day arginine Placebo TC ↔ 
(2009)   (Yes)     hypertriglyceridemia   TG ↔ 
           LDL-c ↔ 
           HDL-c↔ 
Bogdanski Poland 60 Parallel Both 42.4 38.35 13 Obese 9 g/day arginine Placebo LDL-c ↔ 
(2012)   (Yes)        HDL-c↔ 
            
Rahimi Iran 33 Parallel Both 50.89 29.07 13 T2DM 3 g/day arginine Placebo TC ↔ 
(2014) a   (Yes)        TG ↔ 
           LDL-c ↔ 
           HDL-c↔ 
Rahimi Iran 35 Parallel Both 51.98 28.55 13 T2DM 6 g/day arginine Placebo TC ↓ 
(2014) b   (Yes)        TG ↔ 
           LDL-c ↓ 
           HDL-c↔ 
Suliburska Poland 88 Parallel Both 42.3 36.45 26 Obese 9 g/day arginine Placebo TC↔ 
(2014)   (Yes)        TG ↔ 
            
Pahlavani Iran 52 Parallel Male 20.86 23.67 7 Healthy 2 g/day arginine Placebo TC ↓ 
(2014)   (Yes)        TG ↓ 
           LDL-c↓ 
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           HDL-c↑ 
            
PourghassemGargari Iran 34 Parallel Women 35.2 31.80 6 Obese HDEL + 5 g/day HDEL TC ↔ 
(2015) a   (Yes)      arginine  TG ↔ 
           LDL-c ↔ 
           HDL-c↔ 
PourghassemGargari Iran 34 Parallel Women 35.3 32.45 6 Obese HDEL + 5 g/day HDEL + 200 TC ↔ 
(2015) b   (Yes)      arginine + 200 µg/day µg/day TG ↔ 
         selenium selenium LDL-c ↔ 
           HDL-c↔ 
Dashtabi Iran 41 Parallel Both 42.36 35.44 8 Obese 3 g/day arginine Placebo TC ↓ 
(2016) a   (Yes)        TG ↔ 
           LDL-c ↓ 
           HDL-c↔ 
Dashtabi Iran 42 Parallel Both 43.23 34.09 8 Obese 6 g/day arginine Placebo TC ↓ 
(2016) b   (Yes)        TG ↓ 
           LDL-c ↓ 
           HDL-c↑ 
Monti Italy 56 Parallel Both 56.4 35 77 Subjects 6.4 g/day arginine Placebo TC ↔ 
(2018)   (Yes)     with impaired   TG ↔ 
        glucose tolerance and   LDL-c ↔ 
        metabolic syndrome   HDL-c↔ 
Bahrami Iran 56 Parallel Both 50.7 30 13 Metabolic syndrome 5 g/day arginine Placebo TC ↔ 
(2019)   (Yes)        TG ↓ 
           LDL-c ↔ 
           HDL-c↔ 
 
Table 2. Characteristics of included studies 
 
 
RCT, randomized controlled trial; BMI, body mass index; T2DM, type 2 diabetes mellitus; TC, total cholesterol; TG, triglyceride; LDL-c, low-density lipoprotein cholesterol; HDL-c, low-density 
lipoprotein cholesterol. 
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Table 3. Quality assessment of included studies based on Cochrane guidelines 
 
 
Study Random Allocation Blinding of Blinding of Incomplete Selective Other Overall 
 Sequence concealment participants, outcome outcome outcome sources quality 
 Generation  personnel assessment data reporting of bias  
Clarkson Low Unclear Low Unclear Low Unclear Unclear Fair 
(1996)         
Blum Low Unclear Low Unclear Unclear Low Unclear Fair 
(2009)         
Lucotti Low Low Low Low Low Low Low Good 
(2009)         
Schulze Low Low Low Unclear Low Low Unclear Good 
(2009)         
Bogdanski Low Low Low Unclear Low Low Low Good 
(2012)         
Rahimi Low Unclear Low Unclear Low Unclear Unclear Fair 
(2014)         
Suliburska Low Low Low Unclear Low Low Low Good 
(2014)         
Pahlavani Low Low Low Low Low Low Low Good 
(2014)         
PourghassemGargari Low Low Low Low Low Low Low Good 
(2015)         
Dashtabi Low Low Low Unclear Low Low Unclear Good 
(2016)         
Monti Low Low Low Unclear Low Low Low Good 
(2018)         
Bahrami Low Low Low Unclear Low Low Low Good 
(2019)         
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Table 4. Result of subgroup analysis of included studies in meta-analysis. 
 
 Sub-grouped by  No. of  Effect  95% CI   I
2
 (%)  P for  P for 
         trials  size1              heterogeneity  Effect size 
 TC                             
 Mean age                             
 ≥50 years  6   -7.47     -19.97, 5.04    72.5   ˂0.001  0.24   
 ˂50 years  7   -2.66     -8.46, 3.14     0.0    0.97   0.41   
 Baseline BMI                             
 ≥30 kg/m2  8   -0.23     -5.01, 4.54     0.0    0.97   0.92   
 ˂30 kg/m2  5   -11.95   -26.64, 2.75    68.5   0.01   0.16   
 Intervention duration                             
 ≥10 weeks  6   -7.38     -18.78, 4.02    72.4   ˂0.001  0.20   
 ˂10 weeks  7   -2.72     -8.81, 3.36     0.0    0.96   0.43   
 Dose                             
 ≥6 g/day  6   -7.74     -19.74, 4.25    71.9   ˂0.001  0.26   
 ˂6 g/day  7   -2.69     -8.61, 3.23     0.0    0.94   0.37   
 Health status                                
                                  
  Dyslipidemia   2   -1.80     -25.28, 21.69   0.0    0.48   0.88   
                               
  T2D/MetS   4   -12.58   -28.19, 3.02     65.2   0.03   0.11   
                               
  Other   7   -0.79     -5.09, 3.51     0.0    0.94   0.71   
                              
 TG                             
 Mean age                             
 ≥50 years  6   -9.08     -16.70, -1.45   36.7   0.16   0.02   
 ˂50 years  7   -3.56     -10.91, 3.79    0.0    0.98   0.31   
 Baseline BMI                             
 ≥30 kg/m2  8   -9.86     -16.22, -3.50   0.0    0.50   ˂0.001 
 ˂30 kg/m2  5   -4.51     -10.54, 1.53    0.0    0.63   0.13   
 Intervention duration                             
 ≥10 weeks  6   -9.21     -15.20, -3.21   12.0   0.33   ˂0.001 
 ˂10 weeks  7   -3.09     -10.53, 4.35    0.0    0.81   0.38   
 Dose                             
 ≥6 g/day  6   -5.50     -12.58, 1.58    0.0    0.76   0.11   
 ˂6 g/day  7   -7.89     -15.04, -0.73   18.9   0.28   0.03   
 Health status                              
                           
  Dyslipidemia   2   26.73    -34.47, 87.93   13.5   0.28   0.39   
                         
  T2D/MetS   4   -11.77   -19.39, -4.14    17.9   0.30   ˂0.001  
                               
  Other   7   -3.46     -9.50, 2.23     0.0    0.99   0.22   
                              
 LDL-c                             
 Mean age                             
 ≥50 years  6   -0.44     -7.23, 6.34     42.1   0.12   0.89   
 ˂50 years  7   -1.69     -6.31, 2.93     0.0    0.94   0.44   
 Baseline BMI                             
 ≥30 kg/m2  8   2.39     -1.93, 6.71     0.0    0.75   0.21   
 ˂30 kg/m2  5   -3.66     -8.22, 0.90     0.0    0.53   0.10   
 Intervention duration                             
 ≥10 weeks  6   -0.17     -6.58, 6.24     42.5   0.12   0.95   
 ˂10 weeks  7   -2.00     -6.75, 2.76     0.0    0.96   0.38   
 Dose                             
 ≥6 g/day  6   -0.48     -7.82, 6.87     47.1   0.09   0.85   
 ˂6 g/day  7   -1.65     -6.21, 2.91     0.0    0.98   0.47   
 Health status                              
                            
  Dyslipidemia   2   6.1      -17.79, 29.79   0.0    0.99   0.62   
                            
  T2D/MetS   4   -4.47     -11.68, 2.73     13.8   0.32   0.22   
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  Other      7  0.82  -2.81, 4.44  0.0    0.58    0.66 
                       
 HDL-c                      
 Mean age                      
 ≥50 years  6 -0.15  -2.77, 2.47  51.0   0.07    0.90 
 ˂50 years  7 1.29  -0.62, 3.21  58.0   0.05    0.21 
 Baseline BMI                      
 ≥30 kg/m2  8 0.36  -2.03, 2.75  81.2   ˂0.001  0.76 
 ˂30 kg/m2  5 1.24  -1.51, 3.99  0.0    0.96    0.36 
 Intervention duration                      
 ≥10 weeks  6 -0.85  -3.28, 1.58  48.9   0.08    0.49 
 ˂10 weeks  7 2.04  0.52, 3.56  25.6   0.23    0.01 
 Dose                      
 ≥6 g/day  6 -0.25  -4.36, 3.87  86.0   ˂0.001  0.90 
 ˂6 g/day  7 1.18  -0.16, 2.52  0.0    0.96    0.08 
 Health status                         
                          
  Dyslipidemia   2  1.88  -5.26, 9.02  0.0    0.69    0.60 
                         
  T2D/MetS   4  1.25  -1.09, 3.59  0.0    0.93    0.29 
                       
  Other   7  0.21  -2.42, 2.85  83.8   ˂0.001   0.87 
                             
1
Calculated by Random-effects model 
BMI, body mass index; TC, total cholesterol; TG, triglyceride; LDL-c, low density lipoprotein cholesterol; 
HDL-c, low-density lipoprotein cholesterol. 
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